drugset
drugset / Trial / NCT03627195

A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia

NCT03627195 ↗

Phase 1 Completed 40 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

A study to determine the maximum tolerated dose of an investigational drug in subjects with schizophrenia

Timeline

Start
2018-06-07
Primary completion
2019-03-29
Completion
2019-03-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 30 mg —
Subject Lurasidone Small molecule 75 mg —
Subject Lurasidone Small molecule 150 mg —
Subject Lurasidone Small molecule 300 mg —
Subject Lurasidone Small molecule 450 mg —

Indications

schizophrenia